Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 55

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 55
---
 we consider relevant may be incorrect, which may negatively impact our ability
to develop and market our drug candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our
ability to develop and market our drug candidates.

In addition, if we fail to identify and correctly
interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle
or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be
significant, we may be temporarily or permanently prohibited from commercializing any of our drug candidates that are held to be infringing.
We might, if possible, also be forced to redesign drug candidates so that they no longer infringe the third-party intellectual property
rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources
that we would otherwise be able to devote to our business and could adversely affect our business, financial condition, results of operations
and prospects.

Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could negatively impact the success of our business.

Our commercial success depends upon our ability
to develop, manufacture, market and sell our drug candidates and use our proprietary technologies without infringing, misappropriating
or otherwise violating the intellectual property and other proprietary rights of third parties. There is considerable intellectual property
litigation in the pharmaceutical industry. We may become party to, or be threatened with, future adversarial proceedings or litigation
regarding intellectual property rights with respect to our drug candidates and their manufacture and our other technology, including reexamination,
interference, post-grant review, inter partes review or derivation proceedings before the USPTO or an equivalent foreign body.
Numerous U.S.- and foreign-issued patents and pending patent applications owned by third parties exist in the fields in which we are developing
our drug candidates. Third parties may assert infringement claims against us based on existing patents or patents that may be granted
in the future, regardless of their merit.

We do not believe that either BIV201 or bezisterim
(NE3107), the product candidates we are currently developing, infringe the patents of any third parties. However, there can be no assurance
that our technology will not be found in the future to infringe the patents of others. Moreover, patent applications are in some cases
maint